EUVIMEDEUVIMED entdecken
Crossref

Primary systemic carnitine deficiency: Phenotypic variability, diagnostic challenges, and long‐term outcomes

Eymen Pınar iD, Tanyel Zubarioglu iD, Hanım Babazade iD, Kağan Çalışgan iD, Mehmet Şerif Cansever iD, Ertuğrul Kıykım iD, Çiğdem Aktuğlu Zeybek iD

Pediatrics International · 2025-01 · 67 (1)

DOI: 10.1111/ped.70211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatrics International, online erschienen am 06.10.2025. Verfasst von Eymen Pınar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey. Hauptthemen laut MEDLINE: Carnitine, Hyperammonemia, Cardiomyopathies, Muscular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary systemic carnitine deficiency (CDSP) is a rare inherited metabolic disorder characterized by impaired carnitine transport due to mutations in the SLC22A5 gene, leading to impaired mitochondrial fatty acid oxidation. The aim of this retrospective, descriptive study was to investigate the clinical, biochemical, and molecular features of CDSP in Turkey, where the lack of a national expanded metabolic screening program contributes to delayed diagnosis and severe complications.

Methods

The clinical, biochemical, and molecular profiles of 12 patients from eight families diagnosed between 2003 and 2025 were retrospectively analyzed. Data on family history, consanguinity, clinical manifestations—including cardiomyopathy, muscle weakness, neurological symptoms, and liver dysfunction—plasma free carnitine levels, and echocardiographic measurements were collected and analyzed.

Results

The majority of patients (92%) were from consanguineous families. Cardiomyopathy was the most common clinical feature (75%), followed by muscle weakness (50%), neurological symptoms (42%), and liver dysfunction (33%). A novel SLC22A5 variant (c.125T>C; p.Leu42Pro) was identified that expands the known genetic spectrum of CDSP. Oral carnitine supplementation significantly increased plasma free carnitine levels ( p = 0.01) and improved long‐term interventricular septal thickness Z‐scores ( p = 0.045). In addition, cholestasis was observed in two patients, suggesting an expanded disease phenotype.

Conclusion

These results emphasize the crucial role of early detection and family screening in the prevention of life‐threatening complications associated with CDSP. Long‐term carnitine therapy improves metabolic and cardiac outcomes, underscoring the need for early intervention and inclusion of CDSP in national newborn screening programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarnitineHyperammonemiaCardiomyopathiesMuscular DiseasesUrea Cycle Disorders, InbornHumansFemaleMaleRetrospective StudiesSolute Carrier Family 22 Member 5Child, PreschoolPhenotypeChildInfantTurkeyMutationAdolescentInfant, NewbornConsanguinity

Stichwörter der Autor:innen

SCL22A5cardiomyopathiescholestasisechocardiographysystemic carnitine deficiency

Substanzen

CarnitineSolute Carrier Family 22 Member 5SLC22A5 protein, human

Autor:innen und Institutionen

  • Department of Pediatrics, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey.
  • Division of Pediatric Nutrition and Metabolism, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey.
  • Research Laboratory of Metabolism, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey.
  • Department of Medical Documentation and Techniques, Division of Medical Laboratory Techniques, İstanbul University-Cerrahpaşa, The Vocational School of Health Services, İstanbul, Turkey.

ORCID-Profile: Eymen Pınar, Tanyel Zubarioglu, Hanım Babazade, Kağan Çalışgan, Mehmet Şerif Cansever, Ertuğrul Kıykım, Çiğdem Aktuğlu Zeybek

Zitieren

APA

Pınar, E., Zubarioglu, T., Babazade, H., Çalışgan, K., Cansever, M. Ş., Kıykım, E., & Aktuğlu Zeybek, Ç. (2025). Primary systemic carnitine deficiency: Phenotypic variability, diagnostic challenges, and long‐term outcomes. Pediatrics International, 67(1). https://doi.org/10.1111/ped.70211

Vancouver

Pınar E, Zubarioglu T, Babazade H, Çalışgan K, Cansever MŞ, Kıykım E, et al. Primary systemic carnitine deficiency: Phenotypic variability, diagnostic challenges, and long‐term outcomes. Pediatrics International. 2025;67(1). doi:10.1111/ped.70211

BibTeX
@article{Pnar2025,
  author = {Pınar, Eymen and Zubarioglu, Tanyel and Babazade, Hanım and Çalışgan, Kağan and Cansever, Mehmet Şerif and Kıykım, Ertuğrul and Aktuğlu Zeybek, Çiğdem},
  title = {Primary systemic carnitine deficiency: Phenotypic variability, diagnostic challenges, and long‐term outcomes},
  journal = {Pediatrics International},
  year = {2025},
  volume = {67},
  number = {1},
  doi = {10.1111/ped.70211}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche